Foghorn Therapeutics Inc. (FHTX) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $2.06 (-1.44%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Dec 17, 2024 | Foghorn Therapeutics to $ | H.C. Wainwright | $13.00 | +531.1% |
| Sep 24, 2024 | Vikram Purohit | Morgan Stanley | $9.00 | +336.9% |
| Aug 19, 2024 | Gavin Clark-Gartner | Evercore ISI | $20.00 | +870.9% |
| Aug 23, 2022 | Vikram Purohit | Morgan Stanley | $15.00 | +628.2% |
Top Analysts Covering FHTX
FHTX vs Sector & Market
| Metric | FHTX | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.60 | 2.25 | 2.41 |
| Analyst Count | 5 | 8 | 19 |
| Target Upside | +94.2% | +153002.0% | +21.5% |
| P/E Ratio | -4.38 | 3.47 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $7M | $9M | $11M | 5 |
| 2027-12-31 | $32M | $45M | $52M | 7 |
| 2028-12-31 | $58M | $59M | $60M | 9 |
| 2029-12-31 | $48M | $70M | $88M | 4 |
| 2030-12-31 | $105M | $154M | $194M | 4 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-0.38 | $-0.29 | $-0.20 | 1 |
| 2027-12-31 | $-1.19 | $-0.99 | $-0.79 | 7 |
| 2028-12-31 | $-1.40 | $-0.82 | $0.13 | 6 |
| 2029-12-31 | $-1.10 | $-0.82 | $-0.48 | 4 |
| 2030-12-31 | $0.02 | $0.03 | $0.04 | 2 |
Frequently Asked Questions
What is the analyst consensus for FHTX?
The consensus among 5 analysts covering Foghorn Therapeutics Inc. (FHTX) is Hold with an average price target of $12.00.
What is the highest price target for FHTX?
The highest price target for FHTX is $20.00, set by Gavin Clark-Gartner at Evercore ISI on 2024-08-19.
What is the lowest price target for FHTX?
The lowest price target for FHTX is $9.00, set by Vikram Purohit at Morgan Stanley on 2024-09-24.
How many analysts cover FHTX?
5 analysts have issued ratings for Foghorn Therapeutics Inc. in the past 12 months.
Is FHTX a buy or sell right now?
Based on 5 analyst ratings, FHTX has a consensus rating of Hold (2.60/5) with a +94.2% upside to the consensus target of $12.00.
What are the earnings estimates for FHTX?
Analysts estimate FHTX will report EPS of $-0.29 for the period ending 2026-12-31, with revenue estimated at $9M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.